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Background: The purpose of this study was to evaluate the clinical benefits and safety of the long-term use of
macrolides in patients with non-cystic fibrosis (non-CF) bronchiectasis.
Methods: Embase, Pubmed, the Cochrane Library and Web of Science databases were searched from inception up
to March 2014. The primary outcome was the improvement of exacerbations of bronchiectasis. Secondary
endpoints included changes of microbiology, lung function, quality of life, sputum volume, adverse events and
macrolide resistance.
Results: The literature search yielded 139 studies, ten of which containing 601 patients were included in this
meta-analysis. Macrolides showed a statistically-significant improvement in reducing acute exacerbations per patient
during follow-up treatment (RR = 0.55, 95% CI: 0.47, 0.64, P < 0.001), increasing the number of patients free from
exacerbations (OR = 2.81, 95% CI: 1.85, 4.26, P < 0.001), and prolonging time to a first exacerbation (HR = 0.38,
95% CI: 0.28, 0.53, P < 0.001). Macrolides maintenance treatment was superior to control with respect to attenuating
FEV1 decline (p = 0.02), improving sputum volume (p = 0.009) and SGRQ total scores (p = 0.02), but showed a higher
risk of adverse events, especially diarrhea (OR = 5.36; 95% CI: 2.06, 13.98, P = 0.0006). Eradication of pathogens was
improved in the macrolide group (OR = 1.76, 95% CI: 0.91, 3.41, P = 0.09), while pathogen resistance caused by
macrolides dramatically increased (OR = 16.83, 95% CI: 7.26, 38.99, P < 0.001). The new appearance of a microbiologic
profile or participant withdrawal due to adverse events showed no significant differences between the two groups.
Conclusion: In patients with non-CF bronchiectasis, macrolide maintenance treatment can effectively reduce frequency
of exacerbations, attenuate lung function decline, decrease sputum volume, improve quality of life, but may be
accompanied with increased adverse events (especially diarrhea) and pathogen resistance.Background
Non-cystic fibrosis (non-CF) bronchiectasis is a respira-
tory disease characterized by persistent airway inflam-
mation and dilation of the bronchial wall driven by
various causes [1]. Patients with bronchiectasis suffer
from sputum production, recurrent exacerbations, and
progressive airway destruction [2]. From 2000 to 2007,
the prevalence of bronchiectasis in the United States
was 1,106 cases per 100,000 with an annual percentage
increase of 8.74% [3]. The average annual hospitalization* Correspondence: jfxucn@gmail.com
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creativecommons.org/publicdomain/zero/1.0/rate was 9.4 per 100,000 in Germany during 2005–2011,
with the highest rate reaching 39.4 hospitalizations per
100,000 among men aged 75–84 years [4].
Major therapy for bronchiectasis is focused on breaking
the “vicious cycle” of mucus stasis, infection, inflamma-
tion, and airway destruction [5,6]. Accumulating evidence
shows that macrolides possess immune-regulatory and
anti-inflammatory functions beyond their anti-microbial
effects [7-10]. Macrolide antibiotics have been effectively
used in the treatment of diffuse panbronchiolitis, COPD
and cystic fibrosis [11-14]. It remains uncertain how well
macrolides can serve in the management of non-CF bron-
chiectasis. More recently, the effects of macrolide antibi-
otics have been reported to be mainly positive in non-CF
bronchiectasis albeit with variable results. However, therele distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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size and study design. This prompted us to systematic-
ally assess the effects of these drugs on patients
with non-CF fibrosis bronchiectasis. The present meta-
analysis was undertaken to determine the efficacy and
safety of macrolide maintenance therapy in non-CF
bronchiectasis patients.
Methods
This review was registered in PROSPERO (CRD42013004656)
(Additional file 1) and performed adhering to PRISMA
guidelines (Additional file 2).
Search strategy
Pubmed, Embase, Web of Science and the Cochrane Li-
brary were comprehensively searched from inception to
March, 2014 by two investigators (L-CF and J-FX), re-
spectively. No language restriction was applied. A Key-
word Search included “Macrolides” or “azithromycin” or
“erythromycin” or “clarithromycin” or “roxithromycin”
and “bronchiectasis” or “non-cystic fibrosis bronchiec-
tasis” or “non-CF bronchiectasis” or “NCFB” and “ran-
domized controlled trial” or “RCT”. In addition, relevant
articles were manually searched and reviewed.
Study selection
The two reviewers (L-CF and H-WL) independently
searched the literature and identified relevant articles for
further assessment of data on efficacy and safety. A
study was considered eligible if (1) it was a clinical ran-
domized controlled trial (RCT); (2) it assessed the effi-
cacy or safety of macrolides in comparison with placebo,
another class of antibiotic or blank control in the treat-
ment of patients with non-CF bronchiectasis. A study
was excluded if (1) it presented as a review article or
protocol; (2) involved patients with chronic respiratory
conditions other than non-CF bronchiectasis, such as
cystic fibrosis, COPD, asthma; (3) the duration of treat-
ment was less than 8 weeks; or (4) the data could not be
extracted with current mathematical methods.
Assessment of validity
A quality assessment of each study was performed by
SL and X-BJ independently according to the Cochrane
Collaboration tool in the Review Manager software.
The details of quality review included: (1) random se-
quence generation (selection bias); (2) allocation con-
cealment (selection bias); (3) blinding of participants
and personnel (performance bias); (4) blinding of outcome
assessment (detection bias); (5) incomplete outcome data
(attrition bias); (6) selective reporting (reporting bias); (7)
other bias. Disagreements were resolved by consensus or
by a third reviewer.Data extraction
Two reviewers (PW and H-WL) independently evaluated
all eligible studies and extracted relevant data. From
each eligible study, a variety of characteristics were re-
corded, including study location, design, number of pa-
tients (male/female), mean age, intervention and duration.
The primary outcome assessed was the changes of non-
CF bronchiectasis exacerbations. A bronchiectasis exacer-
bation was defined as deterioration in cough, dyspnea,
wheezing, fever, chest pain, increased purulent sputum,
requirement for oral or intravenous additional courses of
antibiotics. Secondary outcomes included: quality of life,
lung function, sputum volume, the degree of dyspnea, ad-
verse events, participants withdrawn due to side effects,
changes of microbiologic profile in sputum or bronchoal-
veolar lavage fluid (BALF) or nasal swab, and macrolide
resistance. Attempts were also made to contact authors
for necessary information. If they were not provided, they
were calculated using provided study data. Discrepancies
were resolved by a consensus.
Statistical analysis
The meta-analysis were performed with Review Manager
software (version 5.2; Cochrane Collaboration, Oxford,
United Kingdom) and Stata Statistical software (version
12.0; Stata Corporation, College Station, TX, USA). Most
items of the meta-analysis were performed with Review
Manager software and OR was used as a measure for di-
chotomous. Only the outcomes of time to a first exacerba-
tion and the number of acute exacerbations per patient
were calculated by Stata Statistical software, for publications
did not provide enough data to calculate mean difference
(MD) and 95% CIs in Revman. We only obtained the
data of hazard ratio (HR) and rate ratio (RR) with 95% CI,
respectively. The exact methodology to pooled the data by
Stata was according to Le and Parmar, using the command
“metan lnHR lnll lnul, eform label (namevar = Study)
boxsca (0.9) random xlabel(0.5,1,1.5) effect (“HR”) texts
(250) “to pool the studies. Weighted mean difference
(WMD) or standard mean difference (SMD) are used for
meta-analysis of continuous data. Statistical heterogeneity
among studies was determined by Cochran’s x2 statistics
with P value and I2 throughout the meta-analysis. The value
of p <0.10 or I2 > 50% was suggestive of significant hetero-
geneity, in which case we chose a random-effects model
[15]. Otherwise, calculations were performed with a fixed-
effects model. If substantial heterogeneity was identified,
subgroup analysis was performed to explore heterogeneity.
The publication bias was assessed by the funnel plot.
Results
Literature search
Our initial search identified 55 potentially relevant stud-
ies in Pubmed, 39 studies in Web of Science, 37 studies
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screening titles and abstracts, 45 papers were considered
potentially eligible for full text review. Of these, 35 were
excluded for various reasons, and 10 RCTs [16-25] were
identified for meta-analysis (Figure 1).
Characteristics of included trials
The characteristics of the eligible studies were summa-
rized in Table S1 (see Additional file 3). These studies
were conducted from 1995 to 2011. Both children and
adult patients were included. Patients were either in-
fected with P. aeruginosa or other pathogens. Of all the
RCTs included in the meta-analysis, five studies used
azithromycin in the treatment group [17-19,24,25], two
used erythromycin [16,21], one used clarithromycin [22],
and two used roxithromycin [20,23]. Six out of ten trials
used placebo as control [16-18,20,21,25]. The treatment
duration ranged from 8 weeks to 24 months. Most pa-
tients included in these studies had a history of recur-
rent bronchiectasis exacerbations.
Assessment of risk of bias
Among the included studies, 60% presented random se-
quence generation (6 of 10), 40% reported allocation con-
cealment (4 of 10), 70% had blinded assessment of
participants and personnel (7 of 10), 50% described blind-
ing of outcome assessment (5 of 10), 80% reported incom-
plete outcome data (8 of 10), 90% described the selective
reporting (9 of 10), and 80% were without other bias (8 of
10). Details of the quality assessment are presented in the
supplemental material (see Additional file 4: Figure S1).
Primary efficacy outcome
Ten studies involving 601 non-CF bronchiectasis patients
reported the primary efficacy outcome of macrolides onFigure 1 Flow diagram of the process of selection of included
studies. Flow chart depicts the selection process at each stage.exacerbations. Macrolides treatment resulted in a signifi-
cant reduction in the number of acute exacerbations per
patient compared with control (RR = 0.55, 95% CI: 0.47 to
0.64, P value < 0.001, I2 = 0; Figure 2). When we restricted
only to double blind studies and studies in adults, the
pooled result was 0.55 (95%CI, 0.46-0.65, I2 = 0, p = 0.383)
from three studies [16-18]. Table 1 presents the number
of patients who had acute pulmonary exacerbations strati-
fied by frequencies. Participants who were free from exac-
erbations significantly increased over placebo (OR = 2.81,
95% CI: 1.85 to 4.26, P value <0.001). No evidence of stat-
istical heterogeneity was found for this outcome (I2 = 0,
p = 0.43). In subgroup analysis, there was a statistically-
significant decrease in the number of patients who had at
least three exacerbations in the macrolides group (OR =
0.38, 95% CI: 0.22 to 0.65, P value = 0.0004, I2 = 0), but not
in those who had one exacerbation (OR = 1.18, 95% CI:
0.70 to 2.01, P value = 0.53, I2 = 17%) or two exacerbations
(OR = 0.83, 95% CI: 0.46 to 1.52, P value =0.55, I2 = 34%)
compared with the control group. Relative forest plots
could be found in Additional file 5: Figure S2. Overall,
the pooled result of the number of participants who
had at least one exacerbation was significantly decreased
(OR = 0.36, 95% CI: 0.24 to 0.55, P value <0.01, I2 = 0%;
see Additional file 6: Figure S3).
Secondary efficacy outcomes
Time to a first exacerbation in the macrolide group was
much greater than that in the control group (HR = 0.38,
95% CI: 0.28 to 0.53, P value < 0.001, I2 = 25.3%; see
Additional file 7: Figure S4).
Four studies contributed to the meta-analysis of lung
function. Changes of attenuation in FEV1 decline
(weighted mean difference = 0.02, 95% CI, 0 to 0.04, P
value = 0.02, I2 = 2%) and percent of predicted FEV1
(weighted mean difference = 1.52, 95% CI, 0.49 to 2.56, P
value = 0.04, I2 = 0%) showed statistically-significant dif-
ferences with the macrolides treatment compared with
control. However, there was no significant difference in
change of FVC between the two groups (weighted mean
difference = 0.05, 95% CI, −0.03 to 0.13, P value = 0.25,
I2 = 54%, Table 2).
When patients were treated with macrolide antibiotics,
improvement of quality of life was observed. Stratifying
by the component of St George’s Respiratory Questionnaire
(SGRQ), there were significant differences in the changes of
SGRQ total score (weighted mean difference = −5.39, 95%
CI, −9.88 to −0.89, P value = 0.02, I2 = 84%) and impact
score (weighted mean difference = −5.88, 95% CI, −9.05
to −2.71, P value < 0.001, I2 = 36%). Although there was no
significant difference in other subgroup analyses, there was
a trend of improvement of quality of life in SGRQ symp-
toms (weighted mean difference = −13.38, 95% CI, −30.62
to 3.86, P value = 0.13) and activity score (weighted mean
Figure 2 Analysis of the number of exacerbations. Forest plot assessed Odds Ratio (OR) of acute pulmonary exacerbations as a function of
person-years in patients receiving macrolides compared to control.
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Table 3). A significant difference in the change of dyspnea
was also observed (weighted mean difference = −0.47, 95%
CI, −0.57 to −0.37, P value < 0.001, I2 = 0, see Additional
file 8: Figure S5).
Macrolides maintenance treatments also resulted in
decrease of sputum volume in non-CF bronchiectasis
patients. Among four trials that included results for
the change of 24-hour sputum volume, the weighted
mean difference was −7.38 (95% CI, −12.90 to −1.85,
P value = 0.009, I2 = 80%, Figure 3).
Macrolide treatments showed tremendous variations
in the efficacy of pathogen eradication. In the six trials
that assessed the eradication of H. influenzae, macrolide
antibiotics maintenance therapy was associated with a
significant benefit (OR = 2.06, 95% CI: 1.19 to 3.56,
P value = 0.01, I2 = 27%, Table 4). In the three trials that
assessed the eradication of M. catarrhalis, the result was
also significant (OR = 2.95, 95% CI: 0.99 to 8.78, P value =
0.05, I2 = 38%). Analysis of any common pathogens from
three studies resulted in an OR of 1.76 (95% CI, 0.91 to
3.41,P = 0.09). No significant heterogeneity was detected
(P = 0.23).
In a meta-analysis of the new appearance of five common
pathogens, any reported pathogens showed no statistically-





0 8 135/277 80/267
1 5 37/171 31/164
2 3 24/147 27/142
At least 3 3 34/147 60/142
aNumber of exacerbations per patient; bThe subgroups of at least 1 exacerbations c95% CI: 0.37 to 1.23, P value = 0.20, I2 = 0%). However,
there was a significant risk reduction of new emergence
of M. catarrhalis in patients treated with macrolides
(OR = 0.12, 95% CI: 0.01 to 1.04, P value = 0.05, I2 = 0,
Table 4).
In terms of the microbiologic profile detected in the re-
spiratory secretions at the end of the study, there was a
highly statistically-significant reduction in M. catarrhalis
(OR = 0.15, 95% CI: 0.04 to 0.60, P value = 0.007, I2 = 0)
and S. pneumoniae (OR = 0.41, 95% CI: 0.18 to 0.91, P
value = 0.03, I2 = 52) among patients taking long-term
macrolides versus the control group. The reported organ-
isms showed that there was no statistically-significant
difference (OR = 0.73, 95% CI: 0.41 to .131, P value = 0.30,
I2 = 0%; see Additional file 3: Table S2).
Safety outcomes
Side effects reported by five articles were assessed. The
main adverse effects were analyzed in subgroups (Figure 4).
The risk of diarrhea was found to be statistically higher
among participants receiving macrolides compared to
those receiving placebo (OR = 5.36, 95% CI: 2.06 to
13.98, P value = 0.0006, I2 = 0%). Incidences of nausea or
vomiting (OR = 1.03, 95% CI: 0.49 to 2.20, P value =
0.93, I2 = 31%), headache (OR = 0.80, 95% CI: 0.24 to
2.68, P value = 0.72, I2 = 0%), sinusitis (OR = 0.98, 95%ations
Effect size Heterogeneity
OR(95%CI) P value I2 (%) P
2.81(1.85-4.26) <0.01 * 0 0.43
1.18(0.70-2.01) 0.53 17 0.31
0.83(0.46-1.52) 0.55 34 0.22
0.38(0.22-0.65) 0.0004 * 0 0.45
ontributed to the overall estimate;* It was suggestive of statistical significance.
Table 2 Analysis of changes in lung function before and after treatment
Changesa No. of
studies
No. of patients Effect size Heterogeneity
Macrolide Control WMD (95%CI) P value I2 (%) P value
FEV1(L) 4 109 105 0.02(0–0.04) 0.02* 2 0.38
FEV1,% predicted 3 115 110 1.52(0.49-2.56) 0.004* 0 0.57
FVC(L) 3 98 95 0.05(−0.03-0.13) 0.25 54 0.11
Abbreviations: WMD, weighted mean difference; 95%CI, 95% confidence interval; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity.
achange from baseline to the end of the study; * It was suggestive of statistical significance.
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2.17, 95% CI: 0.66 to 7.19, P value = 0.20, I2 = 0%) were
not statistically different between the macrolides group
and placebo group.
In the four trials that reported patient withdrawal be-
cause of adverse events, no statistical difference was
found in terms of participant withdrawal due to adverse
events among patients taking prophylactic macrolides
compared to those taking placebo (OR = 1.18, 95% CI:
0.33 to 4.19, P value = 0.80, I2 = 0%; see Additional file 9:
Figure S6).
Three studies reported pathogen resistance caused by
the usage of macrolide antibiotics. Significant difference
was observed with macrolides treatment, compared with
control (OR = 16.83, 95% CI: 7.26 to 38.99, P value < 0.001,
I2 = 0%, Figure 5). When patients were treated with macro-
lides, there was an increased risk of macrolide resistance
in H. influenzae (OR = 67.47, 95% CI: 8.49 to 536.02,
P value < 0.001), S. aureus (OR = 5.91, 95% CI: 2.01 to
17.35, P value = 0.001, I2 = 0%) and S. pneumoniae (OR =
11.74, 95% CI: 2.46 to 56.03, P value = 0.002, I2 = 0%). The
pooled estimate involved five pathogens and was signifi-
cantly different (OR = 6.45, 95% CI: 1.81 to 23, P value =
0.004, I2 = 64%, see Additional file 10: Figure S7).
Discussion
Patients with non-CF bronchiectasis suffer from recur-
rent exacerbations, resulting in the destruction of the
airways and reduced quality of life [26]. This meta-
analysis presented evidence for a beneficial effect on pul-
monary exacerbation with macrolides treatment. For the
number of acute exacerbations per patient, our results
show a statistically-significant reduction. Although the







Total 5 213 204
Symptoms 3 146 142
Activity 2 87 84
Impact 2 87 84
Abbreviations: WMD, weighted mean difference. achanges from baseline to the end
of statistical significance.efficacy and safety of macrolides in patients with non-
cystic fibrosis bronchiectasis [27], we actually conducted
from different perspectives. For the primary outcome, al-
though both of us concluded that macrolide therapy
could significantly decrease the number of patients with
exacerbations. In Gao’s study, it assessed the number of
patients with experiencing at least one exacerbations,
while we analyzed the number of patients stratifying by
different exacerbations (Table 1). And we found that the
number of participants free from exacerbation was sig-
nificantly greater, and the number of participants who
had at least 3 exacerbations was significantly less in
macrolide-treated group compared with control group.
Meanwhile, there was no statistical significance of the
number of participants had one and two exacerbations
between the two groups. The details of these results
were not reflected by Gao’s study. There was an in-
creased trend of patients experiencing just one exacerba-
tion in the macrolide group compared with control,
which is attributed to the fact that more patients were
“restricted” to one exacerbation. More patients were
having only 1 but not 2 or 3 exacerbations due to the
usage of macrolides. A meta-analysis performed by Shi
et al. showed that the number of patients who had at
least one exacerbation was significantly greater in the
macrolide treated group [28]. However, the incorrect ex-
traction of data affected the overall accuracy and validity
of this meta-analysis, which was also pointed out by
Serisier and Gao [29,30].
In addition, time to a first exacerbation was significantly
prolonged in patients taking macrolides compared with
placebo. Results for the outcomes suggest that macrolides
can affect the frequency of exacerbations in patients with
non-CF bronchiectasis. Of note, in addition to the eightperiod
Effect size Heterogeneity
WMD (95%CI) P value I2 (%) P value
−5.39(−9.88,-0.89) 0.02* 84 <0.001b
−13.38(−30.62,3.86) 0.13 94 <0.001b
−0.79(−4.67,3.09) 0.69 0 0.71
−5.88(−9.05,-2.71) <0.001* 36 0.21
of the study. bI2 > 50%, a random-effects model was chosen; *It was suggestive
Figure 3 Analysis of the sputum volume. Forest plot assessed Odds Ratio (OR) of changes in 24-hour sputum volume before and after treatment be-
tween treatment group and control.
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bronchiectasis exacerbations among patients taking long
term macrolides, three additional studies showed similar
findings [31-33]. Reduction of exacerbations in patients
with non-CF bronchiectasis contributed to the attenuation
of lung function decline and improvement in quality of
life. As well, both of us found the quality of life was
improved in macrolide group. We evaluated the effects
of macrolide therapy on quality of life stratified by all
components of St George’s Respiratory Questionnaire
(SGRQ). And we found that there were significant
differences in the changes of SGRQ total score (weighted
mean difference = −5.39, 95% CI, −9.88 to −0.89,
P value = 0.02, I2 = 84%) and impact score (weighted mean
difference = −6.13, 95% CI, −8.52 to −3.74, P value < 0.001,
I2 = 36%). But there was no significant difference in SGRQ
symptoms score (weighted mean difference = −13.38,
95% CI, −30.62 to 3.86, P value = 0.13) and activity score
(weighted mean difference = −0.79, 95% CI, −4.67 to 3.09,
P value = 0.69, Table 3). While only SGRQ total score






Anyb 3 39/104 28/99
H. i 6 44/219 23/208
P. a 4 20/161 15/154
S. a 3 5/106 7/102
S. p 2 4/63 7/62
M. c 3 13/130 4/122
Newly appearance
Anyb 4 28/163 36/157
H. i 4 14/163 17/157
P. a 2 6/105 6/103
S. a 2 3/87 1/82
S. pd¼ 1 2/46 0/45
M. c 2 0/87 6/82
Abbreviations: H. i, Haemophilus influenzae; P. a, Pseudomonas aerugiosa; S. a, Stap
OR (95%CI), Odds Ratio (95% confidential interval). aPathogens reported eradicated
dThere was only one study reported S.p resistance, so Heterogeneity of this subgro24-hour sputum volume was significantly decreased in
patients taking macrolides compared with placebo
(weighted mean difference = −7.38, 95% CI, −12.90
to −1.85, P value = 0.009, Figure 3). The reduction of
sputum volume also benefits the improvement of lung
function. The reduction of sputum production could be
associated with the inhibitory effect of respiratory glyco-
conjugate exerted by macrolides [34].
These clinical benefits of macrolides in the treatment
of non-CF bronchiectasis may be associated with a lower
bacterial load. In an analysis of bacterial characteristics
before and after treatment, the pooled estimate showed
that there was a significantly increased eradication of
pathogens in the macrolide group (p < 0.05), while there
was no significant difference in the new emergence of
pathogens between the two groups. Meta-analysis also
showed a statistically-significant reduction of pathogens
in patients treated with macrolide antibiotics at the end
of the study. A meta-analysis of long-term azithromycin
use in patients with chronic lung diseases showed that
azithromycin might decrease colonization of bacteriariod
Effect size Heterogeneity
OR(95%CI) P I2 (%) P
1.76(0.91,3.41) 0.09 31 0.23
2.06(1.19,3.56) 0.01* 27 0.23
1.32(0.63,2.77) 0.46 0 0.63
0.69(0.22,2.12) 0.51 0 0.45
0.50(0.13,1.94) 0.32 38 0.20
2.95(0.99,8.87) 0.05* 38 0.20
0.68(0.37,1.23) 0.20 0 0.51
0.79(0.38,1.63) 0.52 61 0.05
0.98(0.32,3.02) 0.97 35 0.21
1.9(0.34,10.61) 0.47 47 0.17
5.11(0.24,109.51) 0.30 - -
0.12(0.01,1.04) 0.05* 0 0.97
hylococcus aureus; S. p, Streptococcus pneumoniae; M. c, Moraxella catarrhalis;
during study period; bany of the pathogens reported in the included studies;
up could not analysis; *It was suggestive of statistical significance.
Figure 4 Analysis of adverse effects. Forest plot assessed Odds Ratio (OR) of the main adverse effects among non-CF bronchiectasis patients re-
ceiving macrolides compared to control.
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sistent with our findings [35]. The lower bacterial load
during long-term macrolide treatment is considered to be
associated with its immunomodulatory and antibiotic ac-
tivities. Macrolides exert their activity by inhibiting neu-
trophil recruitment, chemical mediator release, virulence
factors production and quorum sensing functions [9].
An important matter of concern in the widespread im-
plementation of the long-term use of macrolides is their
adverse effects. In this meta-analysis, we found that theFigure 5 Analysis of macrolide resistance. Forest plot assessing odds ratio
CF bronchiectasis patients receiving macrolides compared to control.pooled estimate of side effects was significantly greater
in the macrolides treatment group than that in the
control group (P = 0.01). Significantly increased risk of
diarrhea was observed among patients treated with
macrolides. However, it was mostly mild. The incidence
of nausea or vomiting, headache, sinusitis and rash
showed no statistically-significant differences between
the macrolides treatment group and the control group.
In addition, no statistically-significant difference between
the two groups was found in the number of patients(OR) of any antimicrobial resistance caused by macrolide among non-
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et al. reported a small absolute increase in cardiovascular
deaths during 5 days of azithromycin therapy [36]. Trials
addressing this issue were rare; only the BLESS study re-
ported that there was no evidence of macrolides causing
QTc prolongation or arrhythmia. However, to prevent
cardiovascular events, care should be taken and record-
ing ECG to monitor the QT interval should be recom-
mended in clinical practice.
Another critical issue limiting the use of long-term
macrolides therapy is the risk of induction of resistant
bacterial strains, which was especially pointed out by
Serisier DJ [37,38]. Compared with study performed by
Wu et al., our study attempt to strengthen evidence on
the macrolide resistance risk [39]. To our knowledge,
none of the meta-analysis evaluating this important issue
until now. Although trials reported this issue were rare,
we tried to gain some evidence to this important issue.
By meta-analysis, our results showed that macrolides use
was associated with a statistically-significant increase
of antimicrobial resistance. An increased risk of develop-
ment of macrolide-resistant S. pneumonia, S. aureus and
H. influenczae was observed in the meta-analysis. In
subgroup analyses, there was no statistically-significant
difference of eradication in S. pneumonia and S. aureus,
which may be associated with drug resistance, deficiency
of dosage or limitation on the bioactivities of macrolides.
The world-wide prevalence of macrolide resistance in
S. pneumoniae was 16.5% in 1996, 21.9% in 1997 [40]
and 24.6% during 1998–2000 [41]. The rapidly increas-
ing rate of macrolide resistance in S. pneumonia was
coincident with increased macrolide sales [37]. Carriage
of the resistant strain is not only a risk to individuals but
also a threat to the community. A study suggested that
penicillin resistance was associated three times more
strongly with macrolides than with penicillins [42]. There
was evidence that suggested that the increase in penicillin
resistance associated with macrolide use was due to the
carriage of co-resistant strains [42,43]. Transfer of the
resistance gene between strains may be responsible for
the emergence of multidrug resistance among different
bacteria [44]. Emergence of multi-drug resistant strains is
a great risk to the whole community. Therefore, in clinical
practice, the physician should be more cautious to select
the appropriate patients and weigh the clinical benefit
against the risks.
Study limitations
There were some limitations of our meta-analysis. First,
the overall number of patients included in our review was
relatively small. Although we tried to collect all the rele-
vant data, it is hard to ensure that no data were missed.
Secondly, the enrolled patients of each study had different
exacerbations in the past year before inclusion and werein different stages of disease. Nevertheless, it should be
noted that all the included studies were RCTs and the
most pooled results showed no statistically-significant
heterogeneity, which could partly make up for the defect.
Thirdly, treatments of macrolides used in the included
studies were of different types, dosages and durations.
The paucity of studies made it difficult to determine the
dose–response relationship between macrolides and benefits.
Conclusions
Macrolide maintenance treatment could reduce acute pul-
monary exacerbations, decrease sputum production, at-
tenuate lung function decline, improve quality of life and
increase the eradication of pathogens. Meanwhile, macro-
lide maintenance treatment was associated with an increase
in the risk of side effects and antimicrobial resistance.
Patients with frequent exacerbations are prone to be con-
sidered to be prescribed long-term macrolide therapy. They
should be carefully evaluated during the follow up treat-
ment. A balance between clinical benefit and potential de-
velopment of macrolides resistance in pathogens and
adverse events should be well weighed. Novel synthetically-
derived macrolides that preserve anti-inflammatory func-
tions as well as overcome the risk of microbial resistance
are needed to be investigated for the long-term treatment
of chronic inflammatory respiratory diseases. More ran-
domized controlled trials involving larger patient samples
are warranted to confirm the appropriate dosage and dur-
ation of macrolides for non-CF bronchiectasis patients.Additional files
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